01761nas a2200289   4500000000100000008004100001260001300042653001500055653003600070653001200106653002000118653001100138653003000149653002200179653001200201653001500213653004400228653002000272100001300292700001600305700001600321245006300337300001200400490000700412520103800419022001401457       1976                            d  c1976 Jun10aChemotaxis10aComplement Inactivator Proteins10aDapsone10aHot Temperature10aHumans10aHypersensitivity, Delayed10aIntradermal Tests10aleprosy10aLeukocytes10aMacrophage Migration-Inhibitory Factors10aTuberculin Test1 aWard P A1 aGoralnick S1 aBullock W E00aDefective leukotaxis in patients with lepromatous leprosy.  a1025-320 v873 a<p>Serums from patients with lepromatous leprosy show a high incidence of a chemotactic inhibitor. This inhibitor acts directly on leukotactic factors (bacterial chemotactic factor, C3 fragment, and C5 fragment) to render the factors irreversibly inactive. Functionally, the inhibitor acts as a chemotactic factor inactivator. While normal serum shows no inhibitory activity under the conditions employed, inhibitory activity causing more than 30 per cent reduction of the bacterial chemotactic factor was found in the serums from 14 of 19 patients with lepromatous leprosy. Although exceptions were noted, a correlation was found between the presence of the inhibitor and depressed skin reactivity to a series of antigens (Lepromin, Trichophytin, Candida, PPD, and mumps antigen) used for elicitation of delayed-type hypersensitivity reactions. The presence in leprosy serums of this inhibitor may be responsible, at least in part, for some of the defects of cellular inflammatory responses in patients with lepromatous leprosy.</p>  a0022-2143